Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: December 15, 2023
Reporting Period: The filing addresses events occurring between November 16, 2023, and December 15, 2023, specifically regarding Nasdaq listing compliance.
Key Financial Metrics
This filing focuses on stockholders' equity rather than operational performance metrics such as revenue or cash flow.
- Stockholders' Equity (as of Sept 30, 2023): $1,236,558 (Reported in Form 10-Q).
- Stockholders' Equity (Pro Forma as of Oct 31, 2023): $4,240,629.
- Nasdaq Minimum Requirement: $2,500,000.
- Revenue, Profit, Cash Flow, Debt, Margins: The filing text does not provide clear values for these metrics.
Material Changes
The primary material change is the significant increase in stockholders' equity from $1,236,558 to $4,240,629. This increase is attributed to a public offering of the Company's securities that closed on October 4, 2023. This change was necessary to address a deficiency in meeting Nasdaq listing standards.
Outlook, Risks, and Management Commentary
- Listing Compliance Risk: On November 16, 2023, Nasdaq notified the Company of non-compliance with the minimum stockholders' equity requirement (Rule 5550(b)(1)) due to equity falling below $2.5 million.
- Management Action: The Company submitted a compliance plan to Nasdaq on December 15, 2023, including a pro forma balance sheet demonstrating compliance.
- Deadline: The Company was given until January 2, 2024, to submit a plan to regain compliance.
- Unusual Items: The filing highlights the reliance on a recent capital raise to maintain exchange listing status.
Investor Verification Checklist
- Verify the final status of the Nasdaq compliance plan submitted on December 15, 2023.
- Confirm the details and terms of the public offering closed on October 4, 2023, that generated the equity increase.
- Review the attached Exhibit 99.1 (Pro Forma Balance Sheet) for the specific composition of the $4,240,629 equity figure.
- Monitor future filings for any additional Nasdaq correspondence regarding continued listing status.